tiprankstipranks
Trending News
More News >
Arbutus Biopharma Corporation (ABUS)
NASDAQ:ABUS
US Market
Advertisement

Arbutus Biopharma (ABUS) Stock Forecast & Price Target

Compare
1,250 Followers
See the Price Targets and Ratings of:

ABUS Financial Forecast

ABUS Earnings Forecast

Next quarter’s earnings estimate for ABUS is -$0.03 with a range of -$0.05 to -$0.02. The previous quarter’s EPS was $0.01. ABUS beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 51.30% of the time in the same period. In the last calendar year ABUS has Outperformed its overall industry.
Next quarter’s earnings estimate for ABUS is -$0.03 with a range of -$0.05 to -$0.02. The previous quarter’s EPS was $0.01. ABUS beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 51.30% of the time in the same period. In the last calendar year ABUS has Outperformed its overall industry.

ABUS Sales Forecast

Next quarter’s sales forecast for ABUS is $1.39M with a range of $900.00K to $1.80M. The previous quarter’s sales results were $10.74M. ABUS beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 45.99% of the time in the same period. In the last calendar year ABUS has Outperformed its overall industry.
Next quarter’s sales forecast for ABUS is $1.39M with a range of $900.00K to $1.80M. The previous quarter’s sales results were $10.74M. ABUS beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 45.99% of the time in the same period. In the last calendar year ABUS has Outperformed its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on ABUS
TR | OpenAI - 4o
TR | OpenAI - 4o
$3.5
Hold
-2.23%
Downside
Reiterated
08/14/25
AI Generated ArticleAI Generated Article
Citizens JMP Analyst forecast on ABUS
Citizens JMP
Citizens JMP
$5
Buy
39.66%
Upside
Reiterated
03/31/25
Arbutus Biopharma's Strategic Restructuring and Legal Prospects Justify Buy Rating
H.C. Wainwright Analyst forecast on ABUS
H.C. Wainwright
H.C. Wainwright
$5
Buy
39.66%
Upside
Reiterated
01/21/25
Positive Outlook for Arbutus Biopharma: Promising Developments and Financial Strength Justify Buy Rating
Chardan Capital Analyst forecast on ABUS
Chardan Capital
Chardan Capital
$4.5$5
Buy
39.66%
Upside
Reiterated
11/19/24
Arbutus Biopharma's Promising Clinical Trial Results Lead to Buy Rating
Robert W. Baird Analyst forecast on ABUS
Robert W. Baird
Robert W. Baird
$4
Hold
11.73%
Upside
Reiterated
11/06/24
Arbutus Biopharma's Promise and Risks: A Hold Rating Amid Early Trial Success and Legal Uncertainty
Jefferies Analyst forecast on ABUS
Jefferies
Jefferies
$7
Buy
95.53%
Upside
Reiterated
09/04/24
Buy Rating Affirmed for Arbutus Biopharma Amid Positive Legal and Clinical Developments
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on ABUS
TR | OpenAI - 4o
TR | OpenAI - 4o
$3.5
Hold
-2.23%
Downside
Reiterated
08/14/25
AI Generated ArticleAI Generated Article
Citizens JMP Analyst forecast on ABUS
Citizens JMP
Citizens JMP
$5
Buy
39.66%
Upside
Reiterated
03/31/25
Arbutus Biopharma's Strategic Restructuring and Legal Prospects Justify Buy Rating
H.C. Wainwright Analyst forecast on ABUS
H.C. Wainwright
H.C. Wainwright
$5
Buy
39.66%
Upside
Reiterated
01/21/25
Positive Outlook for Arbutus Biopharma: Promising Developments and Financial Strength Justify Buy Rating
Chardan Capital Analyst forecast on ABUS
Chardan Capital
Chardan Capital
$4.5$5
Buy
39.66%
Upside
Reiterated
11/19/24
Arbutus Biopharma's Promising Clinical Trial Results Lead to Buy Rating
Robert W. Baird Analyst forecast on ABUS
Robert W. Baird
Robert W. Baird
$4
Hold
11.73%
Upside
Reiterated
11/06/24
Arbutus Biopharma's Promise and Risks: A Hold Rating Amid Early Trial Success and Legal Uncertainty
Jefferies Analyst forecast on ABUS
Jefferies
Jefferies
$7
Buy
95.53%
Upside
Reiterated
09/04/24
Buy Rating Affirmed for Arbutus Biopharma Amid Positive Legal and Clinical Developments
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arbutus Biopharma

1 Month
xxx
Success Rate
18/36 ratings generated profit
50%
Average Return
-5.41%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -5.41% per trade.
3 Months
xxx
Success Rate
15/34 ratings generated profit
44%
Average Return
+0.96%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 44.12% of your transactions generating a profit, with an average return of +0.96% per trade.
1 Year
Roy BuchananCitizens JMP
Success Rate
18/34 ratings generated profit
53%
Average Return
+6.25%
reiterated a buy rating 5 months ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +6.25% per trade.
2 Years
xxx
Success Rate
23/34 ratings generated profit
68%
Average Return
+18.58%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 67.65% of your transactions generating a profit, with an average return of +18.58% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABUS Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
0
0
0
0
0
Buy
3
2
0
0
0
Hold
1
5
6
7
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
7
6
7
5
In the current month, ABUS has received 0 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. ABUS average Analyst price target in the past 3 months is 3.50.
Each month's total comprises the sum of three months' worth of ratings.

ABUS Stock Forecast FAQ

What is ABUS’s average 12-month price target, according to analysts?
Based on analyst ratings, Arbutus Biopharma Corporation’s 12-month average price target is 3.50.
    What is ABUS’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for ABUS, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is ABUS a Buy, Sell or Hold?
        Arbutus Biopharma Corporation has a consensus rating of Hold which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Arbutus Biopharma Corporation’s price target?
          The average price target for Arbutus Biopharma Corporation is 3.50. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $3.50 ,the lowest forecast is $3.50. The average price target represents -2.23% Decrease from the current price of $3.58.
            What do analysts say about Arbutus Biopharma Corporation?
            Arbutus Biopharma Corporation’s analyst rating consensus is a Hold. This is based on the ratings of 0 Wall Streets Analysts.
              How can I buy shares of ABUS?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis